# Effect of the Administration of L-arginine vs. Placebo in Patients Diagnosed With Presbyvestibulopathy.

> **NCT05932979** · PHASE2 · WITHDRAWN · sponsor: **Centro Universitario de Tonalá**

## Conditions studied

- Presbyvestibulopathy

## Interventions

- **DRUG:** L-arginine
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT05932979
- **Lead sponsor:** Centro Universitario de Tonalá
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2023-05-02
- **Primary completion:** 2023-11-01
- **Final completion:** 2023-12-30
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** the investigation was cancelled because there was no monetary resource to complete it.
- **Last updated:** 2024-02-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05932979

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05932979, "Effect of the Administration of L-arginine vs. Placebo in Patients Diagnosed With Presbyvestibulopathy.". Retrieved via MORVS 2026-10-10 from https://api.morvs.ai/clinical/NCT05932979. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*